Cipla : Schedule of Analysts/Institutional Investor Meet/Con. Call
October 18, 2022 at 05:43 am
Share
17th October 2022
(1) BSE Limited
(2) National Stock Exchange of India Limited
Listing Department
Listing Department
Phiroze Jeejeebhoy Towers,
Exchange Plaza, 5th floor,
Dalal Street,
Plot no. C/1, G Block,
Mumbai 400 001
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: 500087
Scrip Code: CIPLA
SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme
35A Boulevard Joseph II, L-1840 Luxembourg
Sub: Earnings Conference Call
Dear Sir / Madam,
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 4th November, 2022.
This is for your information and records.
Thanking you,
Yours faithfully,
For Cipla Limited
RAJENDR
KUMAR CHOPRA
Digitally signed by RAJENDRA KUMAR CHOPRA Date: 2022.10.17 17:34:22 +05'30'
Rajendra Chopra
Company Secretary
Encl.: as above
Prepared by: Juzer Masta
Cipla Ltd.
Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India
P +91 22 24826000 F +91 22 24826120 Wwww.cipla.com E-mailcontactus@cipla.comCorporate Identity Number L24239MH1935PLC002380
Announcement
Cipla to release Q2FY23 Unaudited Financial Results on November 4, 2022
Date: November 4, 2022
1800 hrs IST - EARNINGS CONFERENCE CALL
The Company will host an earnings conference call at 1800 hrs IST (2030 hrs SST/HKT, 1230 hrs BST, 0830 hrs US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.cipla.com.
Earnings Conference Call Dial-in Information
Date and Time
November 4, 2022 at
1800
- 1900 hrs IST
2030
- 2130 hrs SST/HKT
1230
- 1330 hrs BST
0830
- 0930 hrs US ET
Dial-in Numbers
Universal Access
Primary Access: (+91 22 6280 1562)
(+91 22 7115 8387)
Diamond pass link
Click hereto register
Toll Number
USA: +1 3233868721
UK: +44 2034785524
Hong Kong: +852 30186877
Singapore: +65 31575746
South Africa: +27 110623033
Contact:
Investor Relations
Naveen Bansal
Ankit Bhembre
E-Mail:Investor.Relations@cipla.com
E-Mail:Investor.Relations@cipla.com
Attachments
Original Link
Original Document
Permalink
Disclaimer
Cipla Ltd. published this content on 18 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 October 2022 04:42:07 UTC.
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products.
Net sales by source of income break down between sale of products (96.9%) and services (3.1%).
Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
CIPLA LIMITED 
